KOD Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 110792 min ago

@ $4.87

Išleistas: 14 vas. 2024 @ 20:51

Grąža: -32.55%

Ankstesnis signalas: vas. 14 - 16:33

Ankstesnis signalas: Pardavimas

Grąža: -1.22 %

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 20:21):

Stats
Šios dienos apimtis	241 660
Vidutinė apimtis	834 395
Rinkos kapitalizacija	172.54M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-1.090 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.660
ATR14	$0.00900 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-30	Baker Bros. Advisors Lp	Buy	40 000	Non-Qualified Stock Options (right to buy)
2023-06-30	Yang Taiyin	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Profusek Robert	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Levy Richard S	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Dahiyat Bassil I	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
96.05
Last 99 transactions
Buy: 3 824 931 \| Sell: 1 385 823

Tūris Koreliacija

Ilgas: -0.04 (neutral)

Trumpas: -0.66 (moderate negative)

Signal:(25.672) Neutral

Kodiak Sciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SONN	0.914
VERU	0.908
VNET	0.908
INFI	0.906
DZSI	0.903
LIVN	0.902
TCX	0.902
RYTM	0.901
PCVX	0.899
FNWB	0.897

10 Labiausiai neigiamai susiję koreliacijos
TYHT	-0.933
AAON	-0.913
GSHD	-0.912
PLPC	-0.905
ZGNX	-0.903
CNCE	-0.901
LNTH	-0.9
CPTA	-0.897
LMNR	-0.895
ADMS	-0.893

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Kodiak Sciences Inc Koreliacija - Valiuta/Žaliavos

-0.62
( weak negative )

-0.36
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.49
( neutral )

Kodiak Sciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-25.95M (0.00 %)
EPS:	$-4.97

FY	2023
Pajamos:	$0
Bruto pelnas:	$-25.95M (0.00 %)
EPS:	$-4.97

FY	2022
Pajamos:	$0
Bruto pelnas:	$-11.00M (0.00 %)
EPS:	$6 502.21

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.